NCT04410302 Patient-Derived Xenografts to Reduce Cancer Health Disparities
| NCT ID | NCT04410302 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, Davis |
| Condition | Bladder Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2019-11-12 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2019-11-12 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial/ethnic minorities. Understanding the genetic and response differences among racial/ethnic minorities may help researchers enhance the precision of therapeutic treatments.
Eligibility Criteria
Inclusion Criteria: * Patient receiving treatment for the above 4 cancers (bladder cancer, lung cancer, gastric/stomach cancer, and liver cancer) * Signed informed consent that will be put on file Exclusion Criteria: * No informed consent obtained * Specimen unacceptable/degraded/etc. * Individuals who are not yet adults (infants, children, teenagers) * Pregnant women * Prisoners * Adults unable to consent
Contact & Investigator
Luis G Carvajal-Carmona
PRINCIPAL INVESTIGATOR
University of California, Davis
Frequently Asked Questions
Who can join the NCT04410302 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 100 Years, studying Bladder Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04410302 currently recruiting?
Yes, NCT04410302 is actively recruiting participants. Contact the research team at tfle@ucdavis.edu for enrollment information.
Where is the NCT04410302 trial being conducted?
This trial is being conducted at Orange, United States, Sacramento, United States.
Who is sponsoring the NCT04410302 clinical trial?
NCT04410302 is sponsored by University of California, Davis. The principal investigator is Luis G Carvajal-Carmona at University of California, Davis. The trial plans to enroll 500 participants.